60 Degrees Pharmaceuticals (SXTP) Income from Continuing Operations (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Income from Continuing Operations of 2090155.0 for Q1 2026, down 11.33% year-over-year from 2357350.35 in Q1 2025, and down 113.39% quarter-over-quarter from 979497.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Income from Continuing Operations (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Income from Continuing Operations for 5 consecutive years, with 2090155.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 11.33% year-over-year to 2090155.0; the TTM figure through Mar 2026 stood at 7121618.0 (up 17.1% YoY), while the FY2025 annual figure was 6908764.0, down 9.92% from the prior year.
- Income from Continuing Operations retreated to 2090155.0 in Q1 2026 per SXTP's latest filing, from 979497.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4173542.0 in Q3 2023 and bottomed at 4174226.0 in Q2 2024.
- Historically, Income from Continuing Operations has averaged 1441900.94 across 5 years, with a median of 1961790.5 in 2023.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 387.7% — and 2025, when it slumped 538.65%.
- 60 Degrees Pharmaceuticals' Income from Continuing Operations stood at 371924.0 in 2022, then plunged by 450.17% to 2046217.0 in 2023, then soared by 81.51% to 378287.0 in 2024, then slumped by 158.93% to 979497.0 in 2025, then sank by 113.39% to 2090155.0 in 2026.
- Business Quant data shows SXTP's Income from Continuing Operations at 2090155.0 in Q1 2026, 979497.0 in Q4 2025, and 2317036.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | -2.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.09 Mn |
| Dec 31, 2025 | -979,497.00 |
| Sep 30, 2025 | -2.32 Mn |
| Jun 30, 2025 | -1.73 Mn |
| Mar 31, 2025 | -1.88 Mn |
| Dec 31, 2024 | -378,287.00 |
| Sep 30, 2024 | -2.16 Mn |
| Jun 30, 2024 | -4.17 Mn |
| Mar 31, 2024 | 427,985.00 |
| Dec 31, 2023 | -2.05 Mn |
| Sep 30, 2023 | 4.17 Mn |
| Jun 30, 2023 | -3.34 Mn |
| Mar 31, 2023 | -2.60 Mn |
| Dec 31, 2022 | -371,924.00 |
| Sep 30, 2022 | -1.45 Mn |
| Jun 30, 2022 | -2.15 Mn |